American Society of Hematology Annual Meeting & Exposition (ASH)

Using the International Prognostic Scoring System (IPSS) score and JAK2 mutation status, thrombosis risk could potentially be identified for patients with primary myelofibrosis.

Matthew S. Davids, MD, spoke about which abstracts presented at ASH 2021 he felt were most important.

Lindsey Roeker, MD, spoke about data presented at ASH 2021 and what she thought to be most interesting.

Steven Devine, MD, spoke about which abstracts he found most interesting at ASH 2021.

Patients with triple-class relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel saw a greater survival benefit over physician's choice of treatment.

Most subgroups of patients with relapsed or refractory, heavily pretreated multiple myeloma showed durable responses at the 2-year follow-up to the CARTITUDE-1 trial.

Deep responses were seen with single infusion ciltacabtagene autoleucel for heavily pretreated patients with multiple myeloma who were refractory to lenalidomide.

When asked about abstracts he thinks have the greatest potential to impact the standard of care in myeloma, Rafael Fonseca, MD, looked to emerging cellular therapies, specifically ciltacabtagene autoleucel for the treatment of heavily pretreated disease.

Second-line treatment of lisocabtagene maraleucel demonstrated improved quality of life in patients with large B-cell lymphoma.

Data from a retrospective head-to-head analysis of pacritinib vs ruxolitinib showed that the former was more favorable in terms of symptom response for patients with myelofibrosis and thrombocytopenia.

Patients with cytopenic myelofibrosis produced a tolerable safety profile when receiving treatment with pacritinib.

Patients with relapsed/refractory multiple myeloma continue to experience robust and durable benefit from treatment with ciltacabtagene autoleucel.

Patients with polycythemia vera who have controlled hematocrit and elevated white blood counts can have increased risk of thrombotic events.

YTB323 led to a promising safety profile and encouraging efficacy outcomes for adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Sattva S. Neelapu, MD, spoke about which abstracts he was most excited to see presented at the upcoming American Society of Hematology Annual Meeting.

Ciltacabtagene autoleucel as a single infusion led to early, durable responses, and demonstrated positive minimal residual disease negativity for patients with multiple myeloma who had early clinical relapse.

Patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma did not benefit in terms of event-free survival when treated with the CAR T-cell therapy tisagenlecleucel vs standard-of-care chemotherapy and transplant.

The phase 1b/2 EQUATE study demonstrated high clinical responses to itolizumab for patients with acute graft vs host disease.

Data for ciltacabtagene autoleucel from CARTITUDE-1 show that use in the setting of heavily pretreated multiple myeloma bests standard-of-care treatments.

Treatment with lisocabtagene maraleucel resulted in long-lasting responses in patients with relapsed/refractory large B-cell lymphomas.

Thomas G. Martin, MD, spoke about the updated results of the CARTITUDE-1 study examining ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.

Treatment with the CAR T-cell therapy tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma was favorable in both the pivotal clinical trial and the real-world setting, according to new data made available during 2021 ASH.

A population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia appeared to have comparable real-world benefit from tisagenlecleucel compared with findings from the phase 2 ELIANA trial.

Depression and anxiety notably impact how patients with hematologic malignancies view clinical studies.

Investigators noted that patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were more likely to experience COVID-19 mortality vs non-cancer patients.

A strong antibody response was seen in patients with acute myeloid leukemia and myelodysplastic syndrome who received the mRNA COVID-19 vaccine.

Patients with relapsed or refractory follicular lymphoma who had been given 2 or more prior lines of therapy and received tisagenlecleucel saw positive efficacy responses.

Orca-T improved efficacy outcomes over standard of care therapy for patients with serious hematologic malignancies.

Second-line treatment with liscocabtagene maraleucel improved survival compared with the standard of care for patients with relapsed or refractory large B-cell lymphoma.

Luciano Costa, MD, PhD, spoke about which abstracts he wants to see most at ASH 2021.